PI Industries announces twin acquisitions into Pharma API & CDMO space

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

Taros Chemicals and Welab Barcelona partner for drug Discovery and development services

The combination will support clients in getting their end-to-end discovery and development programs delivered.

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData

FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop

Pfizer acquisition of ADC trailblazer Seagen a worthy investment: GlobalData

Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.

Zydus granted Orphan Drug Designation by USFDA for ZYIL1

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates

PCI Pharma plans Biologics assembly facility in the Midwest

New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies

Lonza upgrades powder characterization capabilities at Tampa

The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months